降低通货膨胀法案的药物价格谈判计划对新药临床开发的激励措施的影响
在PubMed上查看摘要
概括
此摘要是机器生成的。药物价格谈判计划 (DPNP) 显著降低了新药研发投资回报,可能会影响未来的药物开发. 减轻这些影响的策略并没有完全恢复激励.
科学领域
- 健康经济学
- 制药政策
- 药物开发
背景情况
- 药品价格谈判计划 (DPNP) 旨在降低处方药的成本.
- 了解DPNP对药物研发投资的影响对于未来的药物创新至关重要.
研究的目的
- 分析DPNP对药物研发投资激励的影响.
- 模拟DPNP对小分子和生物药物开发的财务影响.
主要方法
- 为DPNP选择的5种假设药物场景进行了建模.
- 风险调整后的净当前价值 (NPV) 和内部回报率 (IRR) 在关键发展里程碑上进行了估计.
- 场景包括疾病区域的变化,发展策略和对DPNP的反应.
主要成果
- DPNP大大降低了估计的投资回报,生物制剂和小分子的净净值降低了14%至95%.
- 这两种药物的内部回报率 (IRR) 均下降了3%至14%.
- 没有模拟的反应完全恢复了DPNP前的投资激励.
结论
- 预计DPNP将对可能被选中的药物产生负面影响.
- 长期减少投资可能会从具有重大影响的项目转移资金.
- 预计对药物开发的未来可能产生深远影响.
相关概念视频
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

